To explore additional mechanisms by which STAT3 inhibition positively impacts amyloid deposition, we further examined whether LLL-12 treatment reduces amyloid-induced oxidative stress and its impact on LRP-1—a key molecule involved with Aβ clearance across the blood–brain barrier (BBB). The gene discussed is STAT3; the disease is amyloidosis.